A New Mexico overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
34.5% of New Mexico adults have obesity (CDC BRFSS 2024; CI 32.1–37.1%, a wide margin) — modestly above the national rate of 33.1% in the same source and year 4. The rate has climbed from 26.3% in 2011: up 8.2 points, roughly a 31% relative increase over 13 years, with both endpoints independently re-verified against CDC BRFSS in this pass 4.
New Mexico's population is 2,130,256 (Census Population Estimates Program, Vintage 2024) 6. Note that the state-level BRFSS figure above and the CDC PLACES place-level estimate used for Albuquerque later on this page are two different, non-comparable methodologies — they should not be read as apples to apples.
Not for the obesity indication under New Mexico Medicaid Fee-for-Service. The NM Health Care Authority's "Weight Reduction Medications" policy page splits weight-reduction drugs into two explicit columns: a "Covered, Prior Authorization Required" column holding only older, non-GLP-1 anti-obesity drugs (benzphetamine, phentermine, sibutramine, mazindol, phendimetrazine, orlistat) — PA requires a BMI over 40, or over 35 with a comorbidity such as hypertension, diabetes, or dyslipidemia, plus a six-month diet-and-exercise trial the page calls "recommended," not required — and a separate "Not Covered by New Mexico Medicaid" column that names Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Imcivree (setmelanotide) explicitly 1.
So New Mexico's flagship GLP-1s for obesity are excluded from FFS Medicaid; only the older, cheaper drug class is covered, and only with prior authorization. This policy is specifically about the obesity/weight-reduction indication — coverage of the same drugs under the separate diabetes indication (Ozempic, Mounjaro) is a different question this page does not answer. The HCA page carries no visible "last reviewed" date; its only dated element is an embedded prior-authorization fax form, MAD Form 635, Rev. 05/15/2023 — a floor for how long this exclusion has stood, not a confirmed effective date 1.
Scope caveat, stated plainly: this is Fee-for-Service only. Most NM Medicaid enrollees are actually in "Turquoise Care" managed care (5 MCOs, including BCBS NM Community Centennial and Molina Healthcare of New Mexico) 2, and whether each MCO's own formulary mirrors this exact FFS exclusion has not been independently checked. HCA's own Preferred Drug List page states a unified statewide PDL is still being procured for 2026, implying formularies are not yet unified across plans 3.
Astra's price in New Mexico is the same as everywhere else we operate: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans ($816 and $1,416 billed annually), the same price at every dose. There is no New Mexico-specific price, surcharge, or discount.
No Albuquerque clinic price-check has been done in this research pass, so this page makes no comparison against a named local provider; that belongs on the Albuquerque city page once it exists with its own sources. For household context, New Mexico's median household income is $67,816 and 10.1% of residents are uninsured (ACS 2024 1-year, via Census Reporter) 7.
The federal frame is verified and consistent across every state Astra operates in: FDA removed tirzepatide from its drug-shortage list December 19, 2024 and semaglutide February 21, 2025; Section 503A compounding enforcement discretion ended shortly after (February 18 and April 22, 2025 for tirzepatide and semaglutide respectively), and 503B ended March 19 and May 22, 2025. Since then, compounding a copy of an FDA-approved GLP-1 is lawful under 503A only for an individual patient whose prescriber documents a clinically significant difference from the approved product. FDA — not state boards — is the citable authority that salt forms such as semaglutide sodium or acetate have no lawful compounding basis.
TODO: New Mexico-specific telehealth-prescribing and compounding rules have not been researched this pass — no NM statute, Medical Board position, or Board of Pharmacy guidance is asserted here. The New Mexico Board of Pharmacy (live-checked August 28, 2026) is the place to check the current rule 8.
Astra is licensed to serve patients in New Mexico, as part of all 50 states.
Albuquerque itself runs slightly below the state figure: 32.9% crude / 33.2% age-adjusted adult obesity prevalence, 2023 BRFSS data via the CDC PLACES 2025 release 5. This is a place-level small-area model estimate, methodologically distinct from New Mexico's raw annual BRFSS figure above — a clean bridge from state to city, not directly comparable decimals.
The full Albuquerque city page is coming soon. Its local clinic price-check and HRSA HPSA designation are open data gaps, out of scope for this pass, so nothing local is published here in the meantime.
Astra treats patients in New Mexico through state-licensed physicians.
Albuquerque's own page is in research and not yet live.
No, not for weight loss. New Mexico Medicaid Fee-for-Service explicitly lists Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Imcivree (setmelanotide) as "Not Covered." The only anti-obesity drugs it pays for, with prior authorization, are older, non-GLP-1 medications like phentermine and orlistat. Coverage under the Turquoise Care managed-care plans most NM Medicaid enrollees actually use has not been separately confirmed.
Astra's price doesn't change by state: $68/month for semaglutide and $118/month for tirzepatide, both on 12-month plans, the same in New Mexico as everywhere else Astra operates. We haven't yet completed a verified local clinic price-check for Albuquerque, so this page doesn't compare against a named local provider — that comparison belongs on the Albuquerque city page once it's researched and sourced.
Federally, compounding a copy of an FDA-approved GLP-1 is lawful only for an individual patient with a prescriber-documented clinical reason, since FDA ended shortage-based compounding flexibility for both drugs in 2025. New Mexico's own Board of Pharmacy rules on this haven't been verified yet — check the board directly for the current state-specific position.
Possibly, but only under narrow federal conditions: a licensed pharmacy may compound a GLP-1 for an individual patient only when the prescriber documents that a compounded version is clinically necessary for that patient specifically. Whether New Mexico adds further state-level restrictions hasn't been confirmed in this research pass.
Yes. Astra is licensed to serve patients across all 50 states, including every part of New Mexico.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.